Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vericel CorpVCEL · Entity 4481 | Chief Medical Officer | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vericel Corp
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,753 |
Last balance in matching sequence
After 2026-06-26 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 2 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 3 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 80,753 F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Row 4 · 2026-06-26 · Sale · Disposed 5,000 · Balance 75,753 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025. F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 25,000 |
Reported balance
After 2026-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 25,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.82 · Expires 2033-02-17 | Direct | 20,000 |
Reported balance
After 2026-06-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-26 · Exercise / conversion · Acquired 5,000 · Balance 20,000 F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.
F3: These options, representing the right to purchase 30,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 17, 2023, which was one quarter after the date on which the option was granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 11,709 | $26.61 | $311,541.36 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,360 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 20,000 | $10.95 | $219,000.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 7,526 | $26.61 | $200,244.28 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,069 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 18,264 | $10.95 | $199,990.80 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 5,000 | $26.27 | $131,373.50 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,331 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 5,000 | $10.95 | $54,750.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 41,652 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000436 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,652 Underlying: Common Stock · 41,652 shares Expires 2030-02-11 F4 · derivative.exercise_date: These options shall begin vesting on February 11, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 7,098 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000436 · primary_01.xml · derivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,098 Underlying: Common Stock · 7,098 shares Expires 2030-02-11 F4 · derivative.exercise_date: These options shall begin vesting on February 11, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 21:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-000436 · primary_01.xml · derivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 11, 2021. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F3 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.